Medical devices, healthcare technology and the business of care
PMA approval · P230011

TruSight Oncology Comprehensive

Illumina, Inc. · Decision date Aug 21, 2024

MEDTECHLEDGER EXPLANATIONP230011

What did the FDA approve?

The FDA approved Illumina's TruSight Oncology Comprehensive as a qualitative in vitro diagnostic using targeted next-generation sequencing on the Illumina NextSeq 550Dx instrument. It detects variants across 517 genes from DNA extracted from formalin-fixed, paraffin-embedded tumor tissue of patients with solid malignant neoplasms, including single nucleotide variants, multi-nucleotide variants, insertions, and deletions. RNA analysis covers fusions in 24 genes and splice variants in one gene, and the test reports a Tumor Mutational Burden score.

The approval statement describes two intended uses: as a companion diagnostic for targeted therapies listed in Table 1 of the statement, and for tumor profiling information used by qualified health care professionals according to oncology guidelines. Genomic findings beyond Table 1 are not conclusive or prescriptive for labeled use of any specific therapeutic product. The database record does not include a supplement type or reason, so no changed item or original PMA relationship is established.

FDA approval order statement

TruSight Oncology Comprehensive is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing to detect variants in 517 genes using nucleic acids extracted from formalin-fixed, paraffin embedded (FFPE) tumor tissue samples from cancer patients with solid malignant neoplasms using the Illumina NextSeq 550Dx instrument. The test can be used to detect single nucleotide variants, multi- nucleotide variants, insertions, and deletions from DNA, and fusions in 24 genes and splice variants in one gene from RNA. The test also reports a Tumor Mutational Burden (TMB) score.The test is intended to be used as a companion diagnostic to identify cancer patients who may benefit from treatment with the targeted therapies listed in Table 1, in accordance with the approved therapeutic product labeling. In addition, the test is intended to provide tumor profiling information for use by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 of the intended use statement are not conclusive or prescriptive for labeled use of any specific therapeutic product.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Aug 21, 2024

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230011
Regulatory pathway
Premarket approval application
Product code
PQP
Decision code
APPR
Decision date
Aug 21, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P230011 received

    Application receipt date recorded by FDA.

  2. P230011 · FDA decision

    APPR

  3. P230011/S008 · Related supplement

    TruSight Oncology Comprehensive

Timeline entries are records held by MedtechLedger for P230011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230011

Product / regulatory recordCompanyPathwayDecision dateSource
Illumina, Inc.PMA supplementSep 4, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Illumina, Inc.

Headquarters
Not reported
Brand website
illumina.com
FDA applicant address
5200 Illumina Way, San Diego, CA, 92122

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records